47O Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice

ConclusionBaseline CS was associated with shorter survival for pts treated with CIT and not explained by measured confounders. These results suggest that avoidance of CS should be considered at the initiation of treatment, when possible and appropriate, to maximize the potential benefits of CIT. Further studies are needed to confirm these observations. Table: 47OPatient characteristics by BL CS use, OS by CS useaNSCLC (n  = 862)aMel (n = 742)aUC (n = 609)CS (n = 258)No CS (n = 604)CS (n = 182)No CS (n = 560)CS (n = 116)No CS (n = 493)Age at CIT start, mean (SD), years68.2 (9.6)68.5 (9.8)66.1 (13.0)66.9 (13.0)73.0 (8.9)72.6 (8.9)Female484528312726Non-Hispanic white717085856875CCI<2858793868183Treatment sequence1L1919908826302L55568105955Stage IV at diagnosis716134aa29aa42aa35aaECOG PS  ≥ 2 at CIT start17159113421BL metastasesLiver271724273424Lung0061562736Bone454028263431Brain2619312152Multivariablebb OS, HR (95% CI), CS use vs. no CS use (reference)Model 11.35 (1.12, 1.62)1.23 (0.97, 1.57)1.47 (1.14, 1.90)Model 21.34 (1.12, 1.61)1.24 (0.97, 1.57)1.44 (1.12, 1.87)BL, baseline; CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.Values are % unless noted.aSignificant missing stage information (22% for aMel, 49% aUC vs. 2% aNSCLC).bMultivariable models adjusted for age at CIT start, stage at diagnosis, race/ethnicity, sex, ECOG PS and CCI at CIT start, treatment sequence, b...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research